DRG Epidemiology's coverage of insomnia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the prevalence of insomnia for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's insomnia forecast will answer the following questions:
Of all people diagnosed with insomnia, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of insomnia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following insomnia subpopulations:
Total DSM-IV prevalent cases by anxiety and mood disorders comorbidity status.
Total DSM-V prevalent cases by anxiety and mood disorders comorbidity status.
Total DSM-IV prevalent cases by obstructive sleep apnea comorbidity status.
Total DSM-V prevalent cases by obstructive sleep apnea comorbidity status.
Total DSM-V prevalent cases by drug-treated status.
Total Prevalence Estimates of Insomnia per 100 People Aged 15 or Older in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Insomnia Over the Next 20 Years
Epidemiology Data
Methods
Total DSM-V Insomnia Prevalent Cases
Total DSM-IV Insomnia Prevalent Cases
Comorbidity Cases
Total Drug-Treated DSM-V Insomnia Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Insomnia
Studies Excluded From the Analysis of Insomnia
Risk/Protective Factors
Risk/Protective Factors for Insomnia
Bibliography
Abbreviations
Glossary
Soundharya M
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
